Strata Critical Medical, Inc. (SRTA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Strata Critical Medical, Inc. stock (SRTA) is currently trading at $4.30. Strata Critical Medical, Inc. PS ratio (Price-to-Sales) is 5.40. Analyst consensus price target for SRTA is $9.62. WallStSmart rates SRTA as Sell.
- SRTA PE ratio analysis and historical PE chart
- SRTA PS ratio (Price-to-Sales) history and trend
- SRTA intrinsic value — DCF, Graham Number, EPV models
- SRTA stock price prediction 2025 2026 2027 2028 2029 2030
- SRTA fair value vs current price
- SRTA insider transactions and insider buying
- Is SRTA undervalued or overvalued?
- Strata Critical Medical, Inc. financial analysis — revenue, earnings, cash flow
- SRTA Piotroski F-Score and Altman Z-Score
- SRTA analyst price target and Smart Rating
Strata Critical Medical, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Strata Critical Medical, Inc. (SRTA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Strata Critical Medical, Inc. (SRTA) Key Strengths (3)
Revenue surging 208.30% year-over-year
74.83% of shares held by major funds and institutions
Trading at 1.30x book value, attractively priced
Supporting Valuation Data
Strata Critical Medical, Inc. (SRTA) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Premium valuation at 5.4x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Strata Critical Medical, Inc. (SRTA) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Price/Book. Valuation metrics including Price/Book (1.30) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 208.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (5.40) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -24.50%, Operating Margin at -42.80%, Profit Margin at -55.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -24.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 208.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SRTA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SRTA's Price-to-Sales ratio of 5.40x sits near its historical average of 5.84x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 12% below its historical high of 6.11x set in Mar 2026, and 0% above its historical low of 5.4x in Mar 2026.
Compare SRTA with Competitors
Top MEDICAL CARE FACILITIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Strata Critical Medical, Inc. (SRTA) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
Strata Critical Medical, Inc. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 67M with 208% growth year-over-year. The company is currently unprofitable, posting a -55.0% profit margin.
Key Findings
Revenue growing at 208% YoY, reaching 67M. This pace significantly outperforms most MEDICAL CARE FACILITIES peers.
The company is unprofitable with a -55.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -10M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Strata Critical Medical, Inc. maintain 208%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact Strata Critical Medical, Inc..
Bottom Line
Strata Critical Medical, Inc. is a high-conviction growth story with revenue accelerating at 208% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -55.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:26:17 AM
About Strata Critical Medical, Inc.(SRTA)
NASDAQ
HEALTHCARE
MEDICAL CARE FACILITIES
USA
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company is headquartered in New York, New York.